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Abstract
Background: Most patients who present with depression are treated in primary care by general practitioners (GPs).
Relapse of depression is common (at least 50% of patients treated for depression will relapse after a single episode)
and leads to considerable morbidity and decreased quality of life for patients. The majority of patients will relapse
within 6 months, and those with a history of relapse are more likely to relapse in the future than those with no
such history. GPs see a largely undifferentiated case-mix of patients, and once patients with depression reach
remission, there is limited guidance to help GPs stratify patients according to risk of relapse. We aim to develop a
prognostic model to predict an individual’s risk of relapse within 6–8 months of entering remission. The long-term
objective is to inform the clinical management of depression after the acute phase.
Methods: We will develop a prognostic model using secondary analysis of individual participant data drawn from
seven RCTs and one longitudinal cohort study in primary or community care settings. We will use logistic regression to
predict the outcome of relapse of depression within 6–8 months. We plan to include the following established relapse
predictors in the model: residual depressive symptoms, number of previous depressive episodes, co-morbid anxiety
and severity of index episode. We will use a “full model” development approach, including all available predictors.
Performance statistics (optimism-adjusted C-statistic, calibration-in-the-large, calibration slope) and calibration plots
(with smoothed calibration curves) will be calculated. Generalisability of predictive performance will be assessed
through internal-external cross-validation. Clinical utility will be explored through net benefit analysis.
Discussion: We will derive a statistical model to predict relapse of depression in remitted depressed patients in
primary care. Assuming the model has sufficient predictive performance, we outline the next steps including
independent external validation and further assessment of clinical utility and impact.
Study registration: ClinicalTrials.gov ID: NCT04666662
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Introduction
Depression is the leading cause of disability worldwide
[1], and most people with depression are treated in
primary care [2]. Around half of patients will experience
a re-emergence of depressive symptoms at some point
after their initial symptoms have improved, and for the
majority of these, this occurs within the first 6 months
[3]. Relapse and recurrence are both terms used to
describe the re-emergence of depressive symptoms
following some level of improvement. Generally, relapse
occurs after some improvement (remission) but before
full recovery [4], whereas recurrence is the onset of a
further, separate episode after full recovery. While there
is no empirically derived temporal cut-off to distinguish
relapse from recurrence, recovery is most commonly
operationalized as following an extended period of
remission; between 6 and 12 months [5]. Relapse, then,
occurs within 6–12 months, while recurrence occurs
beyond 6–12 months [4, 6].
The distinction between relapse and recurrence
provides a useful theoretical framework and there may
be some clinical relevance. The implication is that the
re-emergence of symptoms in relapse is part of the un-
successfully treated index episode of depression, while in
recurrence, it is attributable to a new and separate epi-
sode of depression. When the MacArthur Foundation
Research Network defined these terms, or “change
points,” in 1991 [4, 6], their aim was to provide a frame-
work that might be more consistently applied in the
empirical literature, but also that the framework and
definitions themselves be validated empirically by re-
searchers. There have been limited attempts to do this,
though where this has been attempted researchers have
found some evidence to support their validity [7]. Given
the wide variability in the way in which the terms relapse
and recurrence have been operationalized by researchers,
however, Bockting et al. [5] suggested using the terms
interchangeably to describe the “re-emergence of symp-
toms following a period of relative wellness”. We will
use the term relapse throughout this paper.
There is some evidence that the severity of depression
[8] and risk of further relapse [9–11] increases with each
subsequent depressive episode, highlighting the potential
benefits of intervening early to prevent relapse and re-
currence with a view to improving the overall trajectory
of depression. Efforts to prevent relapse could be im-
proved by an increased ability to predict prognosis and
identify high-risk individuals. Prognosis can be shaped by
multiple factors, and once it is established which factors
are associated with an outcome, the information can be
used to create a multivariable prognostic model. Prognos-
tic models aim to provide individualised risk estimates for
a specified outcome by a particular time conditional on
the individual’s values for multiple prognostic factors (or
predictors) [12]. We currently lack evidence-based tools
to assist clinicians with risk predictions of depressive
relapse.
There have been some previous attempts to develop
relapse prediction models for depression [13–17]. These
pre-existing prognostic models have some drawbacks
with respect to successfully predicting relapse in a pri-
mary care context. Critical appraisal of these studies,
using the Prediction model Risk Of Bias Assessment
Tool (PROBAST), found that the majority of these stud-
ies were at high overall risk of bias [18]. The most sig-
nificant limitations were inadequate sample size,
inappropriate handling of missing data and presentation
of inappropriate performance statistics (calibration and
discrimination not assessed) [18]. Furthermore, the de-
veloped models have either demonstrated insufficient
predictive performance on external validation [13], or
they could not be feasibly implemented in a primary care
setting due to the large number and type of included
predictors [16].
This protocol outlines the methods for the develop-
ment and validation of a novel prognostic model to pre-
dict an individual’s risk of relapse of depression in a
primary care setting. The long-term aim, beyond this
study, is to implement the prognostic model in clinical
practice for use by primary care health professionals to
enable optimal shared decision making with patients.
The model must, therefore, be accurate, generalisable
and effective (i.e. result in demonstrably improved out-
comes for patients). In order to be implemented in prac-
tice, it must also be clinically credible and have face
validity to healthcare professionals and patients.
Objective
The objective is to develop and validate a multivariable
prognostic model to predict relapse within 6 to 8
months in patients with remitted depression in primary
care.
Methods
The methods have been developed in accordance with
those recommended by the PROGnosis RESearch Strat-
egy (PROGRESS) initiative [19, 20], and the prognostic
model will be published according to the Transparent
Reporting of a multivariable prediction model for Indi-
vidual Prognosis or Diagnosis (TRIPOD) Statement [21].
This study will use individual participant data (IPD)
from RCTs and a cohort study; therefore, elements of
the Preferred Reporting Items for a Systematic Review
and Meta-analysis of Individual Participant Data (PRIS
MA-IPD) statement are also relevant [22]. However, this
study is not a systematic review and the aim is not to
provide a summary of a complete body of research and
so not all items are applicable. A Patient and Public
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Involvement (PPI) group of service users have informed
several aspects of this study, including selecting predictors
and their measurement (for example, commenting on the
acceptability of validated diagnostic instruments for de-
pression and anxiety symptoms), definition of outcome,
target patient population and clinical application. The
study has been registered prospectively on ClinicalTrials.-
gov (available: ClinicalTrials.gov ID: NCT04666662).
Source of data
We have formed a cohort using IPD from UK primary
care-based datasets. Along with cohort studies, RCTs are
a recommended source of data for development of prog-
nostic models [23]. We had IPD readily available in a
pragmatic sample of four RCTs (CASPER Plus [24],
REEACT [25], REEACT 2 [26] and COINCIDE [27]),
derived from RCTs carried out within our own research
group. In order to increase the sample size available for
model development, we identified further studies: first,
by searching all the National Institute for Health
Research (NIHR)-funded RCTs of primary care-based
interventions for depression, and second, by reference to
the search results from a recent IPD meta-analysis of
RCTs of depression interventions (this meta-analysis had
searched for studies that had used the CIS-R as a meas-
ure of baseline severity and provided a recent search of
relevant studies) [28].
To be included, we specified that RCTs must:
 Include adult patients (18 years and over) with
depression and measure depressive symptoms at a
minimum of three time-points (to enable diagnosis
of depression, remission, relapse/no relapse). We
excluded RCTs in patient groups with significant
psychiatric or medical comorbidity. We also
excluded feasibility studies (due to limited sample
size and shorter follow-up time associated with
those identified);
 Have sufficient follow-up to allow us to detect
relapse within at least 6 months;
 Use only non-pharmacological interventions (e.g.
psychological, social, behavioural). We excluded
RCTs of pharmacological interventions, as these
were felt likely not to be comparable to the
pharmacological interventions that patients would
be receiving from their primary care healthcare
providers as usual treatment. Trials of
pharmacological interventions often use medication
combinations that would not be routinely prescribed
in primary care and would therefore potentially
reduce the generalisability of the model. Non-
pharmacological interventions are more likely to
affect outcomes in a comparable way;
 Use the Patient Health Questionnaire (PHQ-9) as a
measure of depression.
This search added three further RCTs: COBRA [29],
CADET [30] and Healthlines Depression RCT [31].
Finally, we contacted the authors of the West Yorkshire
Low Intensity Outcome Watch (WYLOW) study, a longi-
tudinal cohort study following-up patients after low-
intensity cognitive behavioural therapy (LiCBT) through
the Improving Access to Psychological Therapies (IAPT)
service [3]. See Table 1 for details of the final included
studies.
All of the included studies had pragmatic and unrestrictive
inclusion criteria, and so are expected to be representative of
the target population. The final PREDICTR dataset is derived
from all arms (control and intervention) of seven randomised
controlled trials (RCTs) of low-intensity primary care-based
interventions for depression (CASPER Plus, REEACT, REEA
CT 2, COINCIDE, CADET, COBRA, Healthlines) and one
observational cohort study (WYLOW).
Participants
Adult participants (aged 18 years and over) with depres-
sion. The included participants do not have significant
psychiatric comorbidity (e.g. schizophrenia, bipolar
affective disorder).
Setting
All data sources are primary care or community-based.
Start-point (remission)
There are three important time-points: baseline for the
RCT (i.e. the point at which patients were depressed);
follow-up 1 (FU1; to diagnose remission; t=0 for our
prediction model study and corresponds with a 4-month
follow-up for RCTs) and follow-up 2 (FU2; the intended
prediction time and occurs at either 6 or 8 months after
t=0; patient either relapses or does not relapse).
In all RCTs, the majority of participants are expected
to meet criteria for a diagnosis of depression at baseline.
Any participants identified to have a baseline PHQ-9 less
than 10 will be excluded from the analysis. As described,
FU1 is required to detect “remission” and FU2 to detect
“relapse/no relapse.”
The start-point (or time of intended prediction) is
FU1, the point at which a patient, who started treatment
with case-level depression, has entered remission. The
PHQ-9 is a screening tool for major depressive disorder
and a cut-off of 10 or more is used to detect clinically
significant depressive symptoms [32]. Remission will be
identified as a participant who had case-level depression
at baseline (a PHQ-9 score of 10 or more) having (i) a
post-treatment PHQ-9 score below the established cut-off
of 10 at 4 months after trial baseline (this is consistent
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with clinical recovery [30] as currently operationalized in
the NHS Improving Access to Psychological Therapies
(IAPT) service [3]) and (ii) an improvement of ≥5 points
on the PHQ-9 (which aligns with the established reliable
change index used to identify those with “reliable im-
provement” [33]).
End-point (relapse)
Patients will be coded as relapsed if they fulfil the fol-
lowing criteria within 6 to 8 months post-remission: (i)
PHQ-9 score above the diagnostic cut-off (10 or more)
and (ii) ≥5 points greater than their symptom score at
the time of remission. As above, this is consistent with
accepted criteria for reliable and clinically significant de-
terioration [33, 34].
The main reason for specifying the prediction end-
point at 6 to 8 months rather than a single-time point is
pragmatic and based on the available data (the time be-
tween FU1 and FU2 is 8 months for six of the seven
RCTs and 6 months for COBRA). As discussed in the
“Introduction” section, relapse is most commonly
operationalized as occurring between 6 and 12 months
post-remission [35] and the majority of patients who do
relapse do so within the first 6 months [3]. Relapse by
6–8 months is felt to be an appropriate and sufficiently
short-term timeframe for predictions to be meaningful
and clinically useful for patients and primary care
professionals.
Predictors
We identified predictors based on literature review and
on clinical grounds through discussion of a multidiscip-
linary group including members of the research team
and the PPI group supporting the project. Umbrella
reviews (reviews of other systematic reviews and meta-
analyses) are one of the highest levels of evidence for de-
termining associations between predictors and outcomes
when selecting predictors for inclusion in a prognostic
model [36]. A recently published umbrella review of
prognostic factors associated with increased risk of re-
lapse and recurrence guided the selection of candidate
predictors for inclusion in the model [37]. A further sys-
tematic review of prognostic factors, published after the
umbrella review, supported those findings and was also
used to guide our included predictors [38]. In addition
to this, we reviewed all existing prognostic models for
predicting relapse or recurrence to explore other predic-
tors used [18]. All candidate predictors are based on
self-report or clinical information, and we have not in-
cluded, for example, biomarkers and in-depth neuro-
psychological testing in an effort to ensure that the
model is acceptable and usable in a primary care setting
[39].
Table 1 Summary of primary sources of IPD
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All included studies have information about key pre-
dictors, measured using reliable and validated tools. See
the “Missing Data” section for details of how missing
predictor information will be handled. Categorisation of
continuous predictors will be avoided in order to avoid
loss of information and power to detect an association
between predictors and outcomes [19].
The following variables have robust evidence for their
role as relapse predictors and will be included in the
model (Table 2).
PHQ-9 score at remission (residual depressive symptoms)
Residual depressive symptoms is a strongly established
predictor of relapse [37, 38] and will be operationalized
in this study using the Patient Health Questionnaire
(PHQ-9) score. The PHQ-9 is a validated tool for
screening and case-finding for depression [32], routinely
used in primary care. Remission is defined as a PHQ-9
score below 10 (remission), and residual symptoms are
defined as a PHQ-9 at remission of between 5 and 9
[33]. Per the inclusion criteria for this study, all partici-
pants will meeting criteria for remission (i.e. PHQ-9
score of below 10); PHQ-9 score at remission (0–9) will
be modelled as a continuous variable rather than binary
(e.g. presence or absence of residual symptoms).
Number of previous episodes of depression
There is strong evidence that this is a significant pre-
dictor [37, 38], albeit slightly less strong than for residual
symptoms. We plan to model this as a dichotomous pre-
dictor. The coding of this variable in the original RCTs
is variable (i.e. a combination of continuous and dichot-
omous), and so it would not be possible to model as a
continuous variable in this study. While there is some
weak evidence that the relapse risk increases with each
successive depressive episode, the prognostic effect of
previous episodes on recurrence is strongest when com-
paring any number of previous episodes to no previous
episodes [37]. This finding from the pre-existing litera-
ture is likely to be helpful for a primary care-based prog-
nostic model, as there is potential difficulty in achieving
a precise number of previous episodes in clinical
practice. In this study, we will model this predictor as a
dichotomous variable (0=no previous episodes, 1=one or
more previous episodes) and will accept patient report,
GP report or documentation in GP records.
Comorbid anxiety
There is good evidence that comorbid anxiety predicts
relapse or recurrence of depression and will be included
as a predictor in the model [37, 38]. The GAD-7 is a
valid tool for screening and assessing severity of Gener-
alised Anxiety Disorder score in clinical practice [40].
Pre-treatment symptoms (i.e. those at baseline) seem to
be more predictive of relapse than those at depressive
remission [38]. The pre-treatment GAD-7 score will be
used provided it is available for all datasets; otherwise,
we will use the GAD-7 at remission (t=0). GAD-7 score
will be modelled as a continuous predictor.
Severity of episode
There is reasonable evidence that the baseline severity of
the index episode is a prognostic indicator of greater
odds of relapse [37]. This will be measured using the
PHQ-9 score at baseline (pre-treatment) rather than that
at the point of prognostication (remission). The PHQ-9
score at the point of depression diagnosis will be mod-
elled as a continuous predictor.
RCT intervention
Because the data are drawn from RCTs, we must be
mindful of the fact that approximately half of the partici-
pants have received a treatment (above usual care) and
the other half have not. Where the treatments were
found to be effective, not modelling the effect of differ-
ent treatments can lead to unreliable risk predictions
when the model is validated in a different population.
Excluding the treated individuals would mean losing half
of the available data, and so a preferable option is to ex-
plicitly model for treatment effect when developing a
prognostic model [41, 42]. The treatments in all RCTs
were acute-phase psychological treatments rather than
relapse prevention interventions, and therefore, we do
not know what their effect on relapse outcomes were.
Table 2 Summary of selected predictors
Predictor Type of data Method of measurement Range of values and coding of predictors
PHQ-9 score at point of remission
(residual depressive symptoms)
Continuous PHQ-9 score at remission (t=0) Range from 0 to 9
Number of previous episodes
of depression
Categorical Patient or GP report
(No previous episodes vs any
previous episodes)
No previous episodes=0; 1 or more previous
episodes=1
Comorbid anxiety Continuous GAD-7 Score 0–21
Severity of episode Continuous PHQ-9 score at baseline 10–27
RCT intervention Categorical Presence or absence of
effective treatment
Remission after receiving control=0; Remission
after receiving intervention=1
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One of the studies [31] did include an element of relapse
prevention beyond the acute phase treatment (advisors
phoned the patients every 2 months to check how they
were getting on and encourage them to keep following
the intervention advice). The interventions are also
heterogeneous, and so it is possible that they affected
relapse outcomes in different ways. To avoid overcom-
plicating the model, we will code the presence or ab-
sence of an effective intervention as a dichotomous
variable. We will define an effective intervention by
whether individual participants entered remission after
receiving an RCT intervention (code=1) or whether they
entered remission after receiving a control (code=0).
Exploratory predictors
We also plan to conduct an exploratory analysis investi-
gating the role of the following less well established pre-
dictors: age; gender; ethnicity; employment status;
relationship status; and multi-morbidity (Table 3). Age,
gender and ethnicity are not well supported by the pre-
existing evidence as being associated with relapse [37,
43, 44], but are routinely collected during RCTs and





Original categories (in RCTs) New categories (PREDICTR) Range of values and
coding of predictors
Age Continuous RCT data
collection/self
report
Not applicable Not applicable
Gender Categorical RCT data
collection/self
report
Unchanged Unchanged Men=0; Women=1
Ethnicity Categorical RCT data
collection/self
report








































None No long-term physical health
condition
No long-term physical health
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often included as predictors in prognostic models [19].
There is weak evidence that employment status [45] and
relationship status [46, 47] may be associated with an in-
creased risk of relapse or recurrence. The National Insti-
tute for Health and Care Excellence (NICE) defines
multi-morbidity as the presence of two or more long-
term mental or physical health conditions [48]. The ex-
tant literature suggests that this is not associated with an
increased risk of relapse or recurrence [44, 49]. The ex-
ploratory predictors described here are relevant to a pri-
mary care setting and, therefore, will be
investigated outside of the planned principal analysis, de-
pending on the completeness of the data and final sam-
ple size.
Sample size
Ensuring an adequate sample size will allow for more
accurate estimation of regression coefficients and reduce
the potential for overfitting. Rules of thumb for calculat-
ing required sample size for prediction models with
binary outcomes (such as ten events per candidate pre-
dictor parameter (EPP)) are now considered too simplis-
tic to provide robust estimates of minimum required
sample size [50]. The actual required sample size is
context-dependent and is informed by several factors.
We used the pmsampsize package in Stata (available
online: https://riskcalc.org/pmsamplesize/) to calculate
our required minimum sample size [51].
The Cox-Snell R2 is a measure of overall model fit and
based on the method of Riley et al. [51] an anticipated
Cox-Snell R2 must be specified when calculating sample
size, usually based on previous studies of similar patient
groups/outcomes. No previous prognostic model study
predicting relapse of depression identified so far has
reported a Cox-Snell R2 and so, to ensure an adequate
minimum sample size, we used the recommended
conservative estimated Nagelkerke R2 of 15% [52]. This
corresponds to a Cox-Snell R2 of 0.0945, assuming an
overall outcome proportion of 0.2, which again is a
conservative estimate based on the literature [3]. We tar-
geted an expected shrinkage factor (S) of 0.9 (to reflect
small optimism in predictor effect estimates), as recom-
mended [52].
To include all predictors, we require 8 predictor param-
eters (P), which corresponds to PHQ-9 score at remission,
previous depressive episodes, co-morbid anxiety, severity
of index episode and RCT Intervention (including 2
parameters for each continuous predictor to account for
potential non-linear trends). Therefore, our minimum re-
quired sample size (n) is 722 (with 145 events) for these
predictors. Our actual sample size exceeds this, and there-
fore, we anticipate that the study will be of a sufficient size
to require minimal shrinkage and provide meaningful esti-
mates of predictive performance.
Missing data
To avoid loss of power and precision, missing data will
be handled using multiple imputation with chained
equations (MICE) [53]. Missing values will be imputed
based on other predictor and outcome values, under a
missing at random assumption, and multiple copies of
the dataset will be created with identical known informa-
tion and different imputed values, reflecting the uncertainty
associated with imputation. Imputation will be undertaken
for each RCT separately, to preserve the clustering of par-
ticipants within trials and any between-trial heterogeneity
in predictor effects and outcome prevalence. We will as-
sume that data are missing at random, unless this appears
inappropriate upon inspection and discussion with original
trialists. We will use the percentage of participants with
one or more missing values to determine the number of
imputations needed, in line with current guidance; at least
20, as long as this is greater than or equal to the percentage
of participants with one or more missing values [19, 54].
Results from non-imputed and imputed data will be com-
pared as a form of sensitivity analysis. Given the selection




The datasets will be combined and harmonised to en-
sure consistency across trials. To assess IPD integrity,
we will compare numbers of participants in each treat-
ment arm with those reported in the primary references.
We will check the relapse rate within each arm and
compare these across datasets. To define the quality of
the IPD for prognostic modelling, we will perform risk
of bias assessment on the included datasets using the
PROBAST [55]. Only the participants, predictors and
outcome domains are pertinent; the analysis domain is
used for assessment of prognostic model development
and validation studies which do not apply to the RCTs
included in this study.
Once remission has been identified this will represent
time t=0. Relapse will then be coded as 0=no relapse, 1=
relapse as described in “End-point” section. Descriptive
statistics will be produced for all predictors and outcome
data. Exploratory univariable analysis will be performed
to evaluate the unadjusted relationship between each
predictor variable and the outcome variable, but not for
the purpose of informing predictor selection. We will ex-
plore percentage of cases that relapse over the different
studies to assess comparability of data sources.
Model development
The model will be developed using a multilevel multivar-
iable logistic regression, with a binary (relapse/no re-
lapse) outcome. Model parameters will be estimated via
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unpenalised maximum likelihood estimation and then
penalised post-estimation using a uniform shrinkage fac-
tor (see later). The modelling will preserve the clustering
of patients within trials, by having a random effect on
the intercept, a random intervention effect and a ran-
dom control effect, also allowing for between-study cor-
relation in these pair of effects. If it is not possible to fit
random effects in the multilevel logistic regression
model, as originally planned, we will explore alternative
modelling approaches. This would initially consist of a
Generalised Estimating Equation model to control for
the clustering without a random intercept. If this is also
not possible, we will perform a single-level analysis with
robust standard errors and accept that the limitation is
that there may be a clustering effect that we are unable
to properly control for.
Stepwise methods for predictor selection are not
generally recommended for prediction models as this
has been reported to remove judgment of the analyst
from the process of model development as well as lead-
ing to estimation bias (estimating the performance of a
prediction model after testing for statistical significance
of predictors in the same data) [36]. We have selected
our key predictors on the grounds of best available
evidence and clinical acceptability, as well as practical
reasons related to data availability. The list of predictors
is felt to be of appropriate length, so we will avoid pre-
dictor selection techniques during model development
and include all predictors regardless of their statistical
significance (“full model” approach) [56]. This will also
apply in the presence of multi-collinearity, which is not
an issue for prediction purposes. We will only consider
the need to exclude predictors due to collinearity if this
is preventing convergence of the estimated model.
The full model approach described has the advantage
of not being overly data-dependent and avoids the risk
of removing clinically important predictors from the
final model [56]. Calibration plots with loess smoothed
calibration curves will be provided. Optimism will be
measured and adjusted for using bootstrapping.
We will explore non-linear relationships in the model-
ling process using multivariable fractional polynomials
(MFPs), a flexible and recommended approach for
modelling continuous predictors in medical datasets.
The other recommended method for modelling continu-
ous predictors is the use of restricted cubic splines, and
while these two methods often result in similar models,
there is some evidence that MFPs perform better than
restricted cubic splines in the presence of simpler rela-
tionships and medium amounts of information, as is the
case here [20, 57]. We have factored in two predictor
parameters (beta coefficients) per continuous variable to
account for this approach, as described in the “Sample
size” section.
Beyond the primary analysis outlined, and dependent
on final sample size, an exploratory analysis will be per-
formed investigating the role of less established relapse
predictors (Table 3). Univariable associations between
these predictors and outcome will be explored and, be-
cause the role of these variables as relapse predictors is
less well understood, predictor selection through step-
wise backward elimination will be used to develop an ex-
ploratory model. With sufficient sample size, stepwise
backward elimination is an acceptable form of variable
selection, performs similarly to other predictor selection
approaches (for example, LASSO [58]) and is more com-
patible with our planned approaches for handling miss-
ing data and exploring non-linear trends. Guidance
suggests using a more liberal p-value than the standard
0.05 for retention [19]; we will use a p-value of 0.157 or
less as a stopping rule (consistent with Akaike informa-
tion criteria (AIC) at one degree of freedom) [59].
Internal validation
The predictive performance and optimism of the devel-
oped model will be assessed. Calibration (a measure of
the agreement between predictions from the model and
observed outcomes) will be assessed by plotting
observed vs predicted risks for groups defined by tenths
of individual predicted risk (calibration plot) and by in-
cluding a loess smoothed calibration curve across indi-
viduals (avoiding grouping). Apparent and optimism-
adjusted calibration-in-the-large and calibration slope
will be estimated. Discrimination (the ability of the
model to differentiate between those who do or do not
relapse) will be assessed using the C (concordance)
index. The C-index assesses the extent to which the
model assigns a higher probability of relapse to a patient
who did eventually relapse in contrast to a patient who
did not. The optimism-adjusted C-index will be derived
using bootstrapping.
Optimism describes the risk of obtaining misleading
measures of predictive accuracy when this is assessed in
the same dataset used for model development, mainly
due to overfitting. Internal validation can be used to pro-
vide optimism-corrected performance statistics can miti-
gate for this effect. Non-parametric bootstrapping will
be used as a means of resampling the original dataset.
This has the advantage, for example over a single split-
sample approach, of allowing all of the data to be used
in model development. Bootstrapping will be performed
within each individual study, and then, these will be
combined to create a new bootstrap sample to ensure
studies are represented evenly for the final analysis. Mul-
tiple imputations for missing data will be performed
within each bootstrap sample.
A bootstrap sample will be created in which the model
development process will be repeated. The performance
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of this model will be evaluated in the bootstrap sample
(bootstrap, or apparent, performance) and in the original
sample (test performance). This process will be repeated
hundreds of times and the average difference between
the bootstrap and test performance for each perform-
ance statistic provides the estimate of optimism for that
statistic. Optimism-adjusted performance statistics will
be derived by subtracting the average optimism estimate
(from bootstrapping) from the apparent performance of
the original model. The uniform shrinkage factor (calcu-
lated as the optimism-adjusted calibration slope) will
then be applied to all estimated predictor effects to pro-
duce a penalised logistic regression model, and the inter-
cept updated to ensure calibration-in-the-large.
Sensitivity, specificity and positive and negative pre-
dictive values for the model will be calculated at risk
thresholds considered potentially clinically relevant. It is
unclear whether the creation of risk groups is in the best
interests of patients, but they are often used to guide
clinical decision making [21]. In the absence of a gold
standard test (as is the case here), the need for and
definition of risk groups will be determined based on
discussion within the research team and through con-
sultation with our PPI group during model development.
We will avoid basing risk thresholds on the data used to
develop the model. The net benefit of the model at par-
ticular thresholds will also be examined using decision
curve analysis and compared to treat all and treat none
decisions [60].
External validation
External validation is the assessment of a model’s pre-
dictive performance in data not used in the development
process and is a measure of a model’s generalisability
and performance in a range of populations and settings.
To conserve information and to allow for all data to be
used for model development, we do not plan to perform
a conventional external validation as part of this study.
We do, however, have IPD from multiple studies, and
therefore, generalisability and heterogeneity of the model
performance will be examined using internal-external
cross-validation (IECV) [61], as follows. We will exclude
data from each primary study in turn and develop the
risk prediction model using the remaining data. We will
then externally validate the developed model using the
data from the excluded study. This process will be
repeated, each time omitting a different study, until the
model has been fitted excluding each study once.
Random effects meta-analysis will then be used to sum-
marise the performance across studies, to obtain sum-
mary measures of the model performance and estimates
of heterogeneity in performance across studies. We will
ensure that each cycle of the IECV approach retains suf-
ficient sample size for model development; in this
manner, each cycle will retain the majority of the avail-
able IPD for model development, and so the final models
produced in each cycle are likely to be similar to each
other. A consistent model development strategy will be
used in each cycle of the IECV approach [62].
A sensitivity analysis will be performed measuring
predictive performance statistics omitting, first, the ob-
servational cohort data (WYLOW) and, secondly, the
RCT (COBRA) with relapse at 6, rather than 8, months.
If our risk of bias (PROBAST) assessment identifies any
studies that are not at overall low risk of bias, we will
also perform a sensitivity analysis omitting these studies.
Discussion
We have reported a protocol for the development and
validation of a novel prognostic model to predict depres-
sive relapse in a primary care setting. As discussed, we
have used an up-to-date review of the extant literature
to guide predictor selection and our sample size is in ex-
cess, relative to the number of predictor parameters, of
those used in previous prognostic model studies. We
now briefly discuss our anticipated next steps, beyond
this prognostic model study.
It is envisaged that this statistical model could form
the basis for a clinical tool, to be embedded in GP IT
systems, to help identify patients who are at higher risk
of relapse. Longer term, and with further research, a de-
cision tool could be developed to help inform decisions
as to which patients with remitted depression should re-
ceive relapse prevention interventions. Provided we are
able to demonstrate sufficient predictive accuracy during
the validation stages, the model should undergo external
validation (in a different dataset, to assess generalizability)
and, ideally, independent validation (by a different re-
search team, to reduce risk of bias). External validation
could be done on either an unrelated retrospective dataset
or, preferably, a prospective dataset collected specifically
for this purpose. Finally, the impact of the model should
be evaluated, and the gold standard way of doing this is
through a randomised controlled trial with clinically
meaningful outcome measures [63].
Qualitative work with stakeholders will be used to de-
cide the extent to which the model can be implemented
and will guide the evaluation of the model in practice,
including plans for impact assessment. In particular,
Cuijpers recently highlighted the importance of assessing
the effect of mental health treatments on patient-defined
outcomes (e.g. quality of life and functional outcomes)
as well as those determined to be important by re-
searchers or clinicians [64]. This is applicable to health
technologies, like prognostic models, and exploring
patient-defined outcomes will form a part of our evalu-
ation process beyond this study.
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Limitations
The ideal dataset for developing a prognostic model is a
prospective, pre-designed cohort study. The advantage
of such an approach is that investigators retain control
over inclusion and exclusion criteria, definition and
measurement of predictors and outcomes, ensure appro-
priate timings, reduce missing data and minimize other
potential biases (for example, selecting bias and blind-
ing). However, the costs (financial and time) of carrying
out a prospective study would be substantial and sec-
ondary analysis of good quality data from RCT and other
cohorts is an accepted alternative [23]. We are mindful
of the potential problems with this approach, particularly
the risk of missing data (that we have planned for) and
the chance that predictors and outcomes may not be re-
corded optimally. We are reliant on the quality of the
initial data collection with respect to this latter point,
and we are confident that the studies included are of a
high standard.
A further common pitfall of RCTs is the narrow eligi-
bility criteria often stipulated which can impact on the
generalizability of any findings to the target population
of interest (in our case, a primary care patient popula-
tion). We are reassured that the eligibility criteria for
included studies were inclusive and pragmatic with rela-
tively small numbers of participants with missing data.
We do however recognise that RCT participants may
differ from the general population in important ways
and results should be interpreted with this in mind.
In the planning stage of this project, we considered
other data sources, in particular the Clinical Practice
Research Datalink (CPRD), a large electronic database of
routinely collected follow-up data from primary care.
Following discussions with CPRD experts at the Univer-
sity of York, it was evident that the coding of measures
of relapse and recurrence were not optimal for identify-
ing patients who relapsed and that this would have lim-
ited our ability to develop a reliable and generalisable
model.
Further limitations relate to measurement of start-
point (remission) and end-point (relapse or not), which
will be measured using PHQ-9 score. The gold standard
would have been to use diagnostic interviews, which
may have been possible with a prospective cohort study.
The PHQ-9 is a validated and widely used tool with
good sensitivity and specificity [65], and the large sample
size (possible because of the use of secondary data ana-
lysis) should compensate for this. A further point to
consider is that the start- and end-points are defined at
the next time-point they were actually measured rather
than necessarily capturing the precise “real-world” mo-
ment of remission. However, this reflects the situation in
general practice, where diagnostic tools will be applied
at patient consultation rather than in real time.
Therefore, we feel this is justifiable and actually mirrors
the clinical picture accurately. We will use the reliable
clinical recovery and deterioration definitions (sample
size allowing) to ensure robust coding of start- and end-
points.
In the event that multilevel modelling with a random
intercept and random effects on the intervention/control
variable is not possible, we will be required to make an
assumption that the effects of the different interventions
and controls in the RCTs were homogenous. It is not
likely that the interventions had a significant effect on
relapse rates, even where they did improve acute depres-
sion symptoms. However, it is possible that one or more
of the interventions (or controls) did exert an effect
on relapse of which we are not aware. We will take a
pragmatic approach to modelling this, following the
steps that we have outlined in the “Methods” section.
A further limitation is that the data we plan to ana-
lyse do not allow for survival analysis, as the follow-
up time-points were insufficiently similar and infre-
quent. However, time to relapse is important and
would increase our understanding; future prospective
work should consider this when designing strategies
for data collection.
There are some predictors not included due to lack of
relevance and usefulness to GPs. For example, neuroti-
cism (the personality trait), childhood maltreatment and
rumination have been found to be associated with in-
creased risk of relapse and recurrence [37], as has dur-
ation of index episode of depression and age at onset of
first episode of depression [66]. These are not routinely
measured in practice and have not been coded for in our
cohorts; they will therefore not be included as predic-
tors. The cohort has been designed to be as undifferenti-
ated as possible to represent a GP case-mix. Increased
predictive performance would be more likely if we were
to be very specific in defining this cohort, but this would
have implications for its utility in the real-world primary
care setting.
In summary, this study will derive a statistical model
aiming to predict relapse. If it demonstrates sufficient
predictive performance, it could be used to guide the al-
location of interventions to prevent relapse in a primary
care setting, improving outcomes for patients and ensur-
ing efficient use of healthcare resources.
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